Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

Impact · against what's priced in

The FTC's contempt claim against Martin Shkreli for violating a pharmaceutical industry ban has no material impact on any specific publicly traded company. While the filing mentions Shkreli traded in 60 pharma stocks, it does not name the companies or suggest any systemic risk to their operations.

Scored by the NIS engine · methodology.

• regulation
• securities fraud
• pharmaceuticals
• antitrust
• contempt of court
• drug pricing
• ftc
• industry ban
• martin shkreli

Search tags